Gene therapy in autoimmune diseases: Challenges and opportunities

Autoimmunity Reviews

Volumn 9, Issue 3, 2010, Pages 170-174

  Leung, Patrick S C ^a   Dhirapong, Amy ^a   Wu, Ping Yi ^a,b   Tao, Mi Hua ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Clinical trials; Gene therapy; Immunomodulation; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

ADENOVIRUS VECTOR; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; ATORVASTATIN; BHT 3009; CHEMOKINE; DNA VACCINE; DOXYCYCLINE; GLUTAMATE DECARBOXYLASE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 10; MYELIN BASIC PROTEIN; PLACEBO; PLASMID VECTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR PLUS FC FRAGMENT RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABSENCE OF SIDE EFFECTS; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; AUTOIMMUNE DISEASE; CHEMOTAXIS; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FUSION GENE; GENE TARGETING; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; MACROPHAGE MIGRATION; MONOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; GENE SILENCING; GENE THERAPY; HUMANS; MULTIPLE SCLEROSIS;

EID: 72149129189     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.10.004     Document Type: Review

References (87)

1. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323 (1990) 570-578
2. Taylor S.R., Salama A.D., Joshi L., Pusey C.D., and Lightman S.L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 60 (2009) 1540-1547
3. Youinou P., and Jamin C. The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 32 (2009) 206-210
4. Guzman Moreno R. B-cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimmun Rev 8 (2009) 585-590
5. Bianco N.R., Kim S.H., Ruffner M.A., and Robbins P.D. Therapeutic effect of exosomes from indoleamine 2, 3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 60 (2009) 380-389
6. La Cava A. Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev 8 (2008) 83-87
7. Ozawa K., Sato K., Oh I., Ozaki K., Uchibori R., Obara Y., et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 30 (2008) 121-127
8. Fernandez D., and Perl A. Metabolic control of T cell activation and death in SLE. Autoimmun Rev 8 (2009) 184-189
9. Liu K., and Mohan C. Altered B-cell signaling in lupus. Autoimmun Rev 8 (2009) 214-218
10. Waldner M.J., and Neurath M.F. Gene therapy using IL 12 family members in infection, auto immunity, and cancer. Curr Gene Ther (2009)
11. Crispin J.C., and Tsokos G.C. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 8 (2009) 190-195
12. Clauw D.J., and Witter J. Pain and rheumatology: thinking outside the joint. Arthritis Rheum 60 (2009) 321-324
13. Hewagama A., and Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 33 (2009) 3-11
14. Tomer Y., and Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun 32 (2009) 231-239
15. Peron J.P., de Oliveira A.P., and Rizzo L.V. It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response. Autoimmun Rev 9 (2009) 1-4
16. Amano K., Leung P.S., Rieger R., Quan C., Wang X., Marik J., et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 174 (2005) 5874-5883
17. Rieger R., and Gershwin M.E. The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 28 (2007) 76-84
18. Rieger R., Leung P.S., Jeddeloh M.R., Kurth M.J., Nantz M.H., Lam K.S., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 27 (2006) 7-16
19. Amaral M.C., and Alves J.D. Pathogenesis of multi-organic failure in autoimmune diseases. Autoimmun Rev 8 (2009) 525-528
20. Askenasy N., Kaminitz A., and Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 7 (2008) 370-375
21. Davies A.J. Immunological tolerance and the autoimmune response. Autoimmun Rev 7 (2008) 538-543
22. Dimitrov J.D., Lacroix-Desmazes S., Kaveri S.V., and Vassilev T.L. Insight into the mechanism of the acquired antibody auto-reactivity. Autoimmun Rev 7 (2008) 410-414
23. Knip M., and Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 7 (2008) 550-557
24. Lleo A., Battezzati P.M., Selmi C., Gershwin M.E., and Podda M. Is autoimmunity a matter of sex?. Autoimmun Rev 7 (2008) 626-630
25. Meyer-Bahlburg A., and Rawlings D.J. B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev 7 (2008) 313-316
26. Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun Rev 8 (2009) 400-404
27. Fiocco U., Sfriso P., Oliviero F., Pagnin E., Scagliori E., Campana C., et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 8 (2008) 76-82
28. Balague C., Kunkel S.L., and Godessart N. Understanding autoimmune disease: new targets for drug discovery. Drug Discov Today (2009)
29. Schadt E.E., Friend S.H., and Shaywitz D.A. A network view of disease and compound screening. Nat Rev Drug Discov 8 (2009) 286-295
30. Biesen R., Demir C., Barkhudarova F., Grun J.R., Steinbrich-Zollner M., Backhaus M., et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 58 (2008) 1136-1145
31. Maier L.M., and Hafler D.A. Autoimmunity risk alleles in costimulation pathways. Immunol Rev 229 (2009) 322-336
32. Jenks S.A., and Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 8 (2009) 209-213
33. Blagbrough I.S., and Zara C. Animal models for target diseases in gene therapy-using DNA and siRNA delivery strategies. Pharm Res 26 (2009) 1-18
34. Eixarch H., Espejo C., Gomez A., Mansilla M.J., Castillo M., Mildner A., et al. Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen. Mol Ther 17 (2009) 897-905
35. Kokot A., Sindrilaru A., Schiller M., Sunderkotter C., Kerkhoff C., Eckes B., et al. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma?. Arthritis Rheum 60 (2009) 592-603
36. Lodde B.M., Mineshiba F., Wang J., Cotrim A.P., Afione S., Tak P.P., et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 65 (2006) 195-200
37. Rachakonda P.S., Rai M.F., and Schmidt M.F. Application of inflammation-responsive promoter for an in vitro arthritis model. Arthritis Rheum 58 (2008) 2088-2097
38. Pessach I.M., and Notarangelo L.D. X-linked primary immunodeficiencies as a bridge to better understanding X-chromosome related autoimmunity. J Autoimmun 33 (2009) 17-24
39. Invernizzi P. Future directions in genetic for autoimmune diseases. J Autoimmun 33 (2009) 1-2
40. Sanchez-Pernaute O., Ospelt C., Neidhart M., and Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 30 (2008) 12-20
41. Bauer J.W., Bilgic H., and Baechler E.C. Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nat Rev Rheumatol 5 (2009) 257-265
42. Plenge R.M. Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. Curr Opin Rheumatol 21 (2009) 262-271
43. Varga J., and Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 5 (2009) 200-206
44. Scaglione B.J., Salerno E., Gala K., Pan M., Langer J.A., Mostowski H.S., et al. Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black mice. J Autoimmun 32 (2009) 14-23
45. Senolt L., Vencovsky J., Pavelka K., Ospelt C., and Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev (2009)
46. Barral A.M., Thomas H.E., Ling E.M., Darwiche R., Rodrigo E., Christen U., et al. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun 27 (2006) 166-173
47. Lan R.Y., Selmi C., and Gershwin M.E. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 31 (2008) 7-12
48. Shternhall-Ron K., Quintana F.J., Perl S., Meivar-Levy I., Barshack I., Cohen I.R., et al. Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun 28 (2007) 134-142
49. Tarner I.H., Neumann E., Gay S., Fathman C.G., and Muller-Ladner U. Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Autoimmun Rev 5 (2006) 148-152
50. Wang J., Wang G., Sun B., Li H., Mu L., Wang Q., et al. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 30 (2008) 222-229
51. Slavin A.J., Tarner I.H., Nakajima A., Urbanek-Ruiz I., McBride J., Contag C.H., et al. Adoptive cellular gene therapy of autoimmune disease. Autoimmun Rev 1 (2002) 213-219
52. Achiron A., and Mandel M. T-cell vaccination in multiple sclerosis. Autoimmun Rev 3 (2004) 25-32
53. Hellings N., Raus J., and Stinissen P. T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmun Rev 3 (2004) 267-275
54. Ziemssen T., and Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev 4 (2005) 460-467
55. Bazzani C., Filippini M., Caporali R., Bobbio-Pallavicini F., Favalli E.G., Marchesoni A., et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev 8 (2009) 260-265
56. Kim W.U., Sreih A., and Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev 8 (2009) 204-208
57. Barabas A.Z., Cole C.D., Barabas A.D., Graeff R.M., Lafreniere R., and Weir D.M. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun Rev 8 (2009) 552-557
58. Stefanelli T., Malesci A., De La Rue S.A., and Danese S. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmun Rev 7 (2008) 364-369
59. Kok M.R., Yamano S., Lodde B.M., Wang J., Couwenhoven R.I., Yakar S., et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Hum Gene Ther 14 (2003) 1605-1618
60. Guichelaar T., ten Brink C.B., van Kooten P.J., Berlo S.E., Broeren C.P., van Eden W., et al. Autoantigen-specific IL-10-transduced T cells suppress chronic arthritis by promoting the endogenous regulatory IL-10 response. J Immunol 180 (2008) 1373-1381
61. Park I.K., Hiraki K., Kohyama K., and Matsumoto Y. Differential effects of decoy chemokine (7ND) gene therapy on acute, biphasic and chronic autoimmune encephalomyelitis: implication for pathomechanisms of lesion formation. J Neuroimmunol 194 (2008) 34-43
62. Melo M.E., Qian J., El-Amine M., Agarwal R.K., Soukhareva N., Kang Y., et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 168 (2002) 4788-4795
63. Gould D., Yousaf N., Fatah R., Subang M.C., and Chernajovsky Y. Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis. Arthritis Res Ther 9 (2007) R7
64. Chen W., Li H., Jia Y., Lv M., Li M., Feng P., et al. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J Autoimmun 28 (2007) 30-40
65. Peng J., Dicker B., Du W., Tang F., Nguyen P., Geiger T., et al. Converting antigen-specific diabetogenic CD4 and CD8 T cells to TGF-beta producing non-pathogenic regulatory cells following FoxP3 transduction. J Autoimmun 28 (2007) 188-200
66. Clement N., Knop D.R., and Byrne B.J. Large-scale adeno-associated viral vector production using a herpes virus-based system enables manufacturing for clinical studies. Hum Gene Ther (2009)
67. Chan J.M., Villarreal G., Jin W.W., Stepan T., Burstein H., and Wahl S.M. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 6 (2002) 727-736
68. Mourich D.V., and Iversen P.L. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing. Curr Opin Mol Ther 11 (2009) 124-132
69. Silva C.L., Bonato V.L., dos Santos-Junior R.R., Zarate-Blades C.R., and Sartori A. Recent advances in DNA vaccines for autoimmune diseases. Expert Rev Vaccines 8 (2009) 239-252
70. Skarica M., Wang T., McCadden E., Kardian D., Calabresi P.A., Small D., et al. Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis. J Immunol 182 (2009) 4192-4199
71. Lobell A., Weissert R., Storch M.K., Svanholm C., de Graaf K.L., Lassmann H., et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J Exp Med 187 (1998) 1543-1548
72. Bar-Or A., Vollmer T., Antel J., Arnold D.L., Bodner C.A., Campagnolo D., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 64 (2007) 1407-1415
73. Garren H., Robinson W.H., Krasulova E., Havrdova E., Nadj C., Selmaj K., et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 63 (2008) 611-620
74. Boissier M.C., and Bessis N. Therapeutic gene transfer for rheumatoid arthritis. Reumatismo 56 (2004) 51-61
75. Bliddal H., Terslev L., Qvistgaard E., Konig M., Holm C.C., Rogind H., et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 35 (2006) 341-345
76. Schatteman L., Gyselbrecht L., De Clercq L., and Mielants H. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. J Rheumatol 33 (2006) 82-85
77. Desai S.B., and Furst D.E. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20 (2006) 757-790
78. Toussirot E., and Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 8 (2007) 2089-2107
79. Mease P.J., Hobbs K., Chalmers A., El-Gabalawy H., Bookman A., Keystone E., et al. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis 68 (2009) 1247-1254
80. Frank K.M., Hogarth D.K., Miller J.L., Mandal S., Mease P.J., Samulski R.J., et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med 361 (2009) 161-169
81. Kochi Y., Suzuki A., Yamada R., and Yamamoto K. Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun 32 (2009) 158-162
82. Lai Kwan Lam Q., King Hung Ko O., Zheng B.J., and Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci U S A 105 (2008) 14993-14998
83. Takanashi M., Oikawa K., Sudo K., Tanaka M., Fujita K., Ishikawa A., et al. Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther 16 (2009) 982-989
84. Padgett K.A., Lan R.Y., Leung P.C., Lleo A., Dawson K., Pfeiff J., et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 32 (2009) 246-253
85. Pauley K.M., Cha S., and Chan E.K. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 32 (2009) 189-194
86. Boumaza I., Srinivasan S., Witt W.T., Feghali-Bostwick C., Dai Y., Garcia-Ocana A., et al. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 32 (2009) 33-42
87. Mease P.J., Wei N., Fudman E., Kivitz A., Anklesaria P., and Heald A.E. Local treatment for inflammatory arthritis: a phase 1/2 clinical study of intra-articular administration of a recombinant adeno associated vector containing a TNFalpha antagonist gene. Arthritis Rheum 56 (2007) S793